Lactiscaesibacillus rhamnosus: The Probiotic Species and What Its Levels May Signal

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

This test measures the presence and amount of Lactiscaesibacillus rhamnosus in your microbiome to guide targeted probiotic or dietary choices. Identifying low levels—linked to higher risk of antibiotic-associated diarrhea, some digestive complaints, and certain urogenital infections—can help you take preventive steps.

Read more →

Understand what your gut health results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

A targeted read on one well-studied probiotic species

The lactiscaesibacillus rhamnosus test analyzes microbial DNA or RNA in a stool sample to determine whether Lacticaseibacillus rhamnosus is present and, if so, at what relative abundance or copy number. Labs typically use targeted quantitative PCR (qPCR) or metagenomic sequencing to detect species‑level signals; standard 16S rRNA testing often reports only at the genus level and may miss strain‑specific details. Results reflect the current ecosystem — they can shift with recent meals, supplements, travel, or antibiotics — so this is a snapshot, not a permanent trait.

Why focus on L. rhamnosus? This species helps acidify the gut environment via lactate production, competes with opportunists, and can interact with the immune system at the mucosal surface. Certain strains (like the well‑studied “GG”) have been evaluated in randomized trials for antibiotic‑associated diarrhea and pediatric atopic conditions, though benefits are strain‑ and context‑specific. Taxonomically, L. rhamnosus was reclassified to the Lacticaseibacillus genus in 2020, which is why naming may differ across reports. While microbiome science is evolving, consistent patterns — stability, diversity, and the presence of select beneficial taxa — remain reliable markers of gut resilience.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Why a single-species lens on this probiotic is useful

Link the biology to everyday experience: if you recently finished antibiotics, switched to a low‑fiber diet, upped fermented foods, or tried a probiotic, this targeted test helps show whether L. rhamnosus is actually present. Low or undetectable levels can occur normally in healthy adults, because many lactobacilli prefer the upper GI tract and are naturally scarce in the colon; still, in some people, detecting L. rhamnosus aligns with better lactic acid production, competitive exclusion of unwanted microbes, and signals of a well‑nourished mucosal lining. Conversely, persistent absence after supplementation may suggest poor persistence — a clue to review fiber intake, timing, or whether a different strain or approach is warranted with a clinician. If you have persistent GI symptoms, this result adds context rather than a diagnosis.

Zooming out, microbiome testing connects to prevention and long‑term health. Gut microbes influence digestion, inflammation, immune tolerance, and even mood via the gut–brain axis. Tracking a sentinel organism like L. rhamnosus over time helps you see how interventions — more prebiotic fiber, different fermented foods, stress management, or changes in medication — map to microbial behavior. The goal isn’t to “max out” one species; it’s to read patterns in your unique ecosystem and use them to guide prudent, personalized care with your health team.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

Reading presence and quantity

Your report typically shows L. rhamnosus as present or absent, plus a relative abundance (e.g., percent of total microbes) or a quantitative estimate (gene copies per gram). Some labs also compare your value to a reference population. In healthy adults not using probiotics, stool levels are often low or undetectable; detection is more common during or shortly after supplementation.

Balanced or “optimal for you” results usually mean this organism is detectable at low relative levels alongside a diverse community. That pattern supports efficient fermentation, healthy short‑chain fatty acid production downstream, and calmer inflammatory signaling. Optimal ranges vary widely by geography, diet, and age; infants, for example, often carry more lactobacilli than adults.

Imbalanced or “dysbiotic” patterns could include very low diversity plus absence of several beneficial taxa; in that context, missing L. rhamnosus is one more piece suggesting a depleted ecosystem. Alternatively, a spike while taking high‑dose probiotics may reflect recent intake rather than durable colonization. These findings are directional — they guide exploration of diet quality, fiber types, and, if symptoms persist, medical evaluation.

What Lactiscaesibacillus rhamnosus testing settles, and what it leaves open

Big picture: single‑species data gains power when paired with broader markers like overall diversity, butyrate‑producing bacteria, fecal calprotectin, or metabolic labs. Viewed across time and interpreted in your clinical context, it can help tailor strategies for digestion, energy, and long‑term gut resilience.

Frequently Asked Questions

References

  1. Zheng J, Wittouck S, Salvetti E, Franz CMAP, Harris HMB, Mattarelli P, O'Toole PW, Pot B, Vandamme P, Walter J, Watanabe K, Wuyts S, Felis GE, Gänzle MG, Lebeer S (2020). A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. *International Journal of Systematic and Evolutionary Microbiology*, *70*(4), 2782-2858. https://doi.org/10.1099/ijsem.0.004107
  2. Szajewska H, Kołodziej M (2015). Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. *Alimentary Pharmacology & Therapeutics*, *42*(10), 1149-1157. https://doi.org/10.1111/apt.13404
  3. Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, Lener E, Mele MC, Gasbarrini A, Collado MC, Cammarota G, Ianiro G (2023). Short-chain fatty-acid-producing bacteria: Key components of the human gut microbiota. *Nutrients*, *15*(9), 2211. https://doi.org/10.3390/nu15092211
  4. Jovel J, Patterson J, Wang W, Hotte N, O'Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong, G. K.-S. (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. *Frontiers in Microbiology*, *7*, 459. https://doi.org/10.3389/fmicb.2016.00459
  5. Drago L (2025). Navigating microbiome variability: Implications for research, diagnostics, and direct-to-consumer testing. *Frontiers in Microbiology*, *16*, 1580531. https://doi.org/10.3389/fmicb.2025.1580531

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey